Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00002540
First received: November 1, 1999
Last updated: November 2, 2016
Last verified: November 2016
Results First Received: August 30, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Investigator);   Primary Purpose: Screening
Condition: Prostate Carcinoma
Interventions: Other: Laboratory Biomarker Analysis
Procedure: Medical Examination
Other: Screening Questionnaire Administration

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled between November 1993 and July 2001 at 10 study centers. Recruitment was done for all four outcomes of the study (prostate, lung, colorectal and ovarian).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants signed a study informed consent prior to being randomized to a study arm.

Reporting Groups
  Description
Control Participants receive standard medical care.
Prostate Screening Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.

Participant Flow:   Overall Study
    Control   Prostate Screening
STARTED   38345   38340 
COMPLETED   37544   35876 
NOT COMPLETED   801   2464 
Cancer Before Rand. (Prostate Screening)                0                25 
Died Before Randomization                2                6 
Died Before ASU (Control)                202                0 
Refused ASU (Control)                597                0 
Refused Screen (Prostate Screening)                0                2433 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Control Participants receive standard medical care.
Prostate Screening Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.
Total Total of all reporting groups

Baseline Measures
   Control   Prostate Screening   Total 
Overall Participants Analyzed 
[Units: Participants]
 38345   38340   76685 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   24390   24400   48790 
>=65 years   13955   13940   27895 
Age 
[Units: Years]
Mean (Standard Deviation)
 62.7  (5.3)   62.7  (5.3)   62.7  (5.3) 
Gender 
[Units: Participants]
     
Female   0   0   0 
Male   38345   38340   76685 
Region of Enrollment 
[Units: Participants]
     
United States   38345   38340   76685 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Prostate Cancer Deaths   [ Time Frame: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years. ]

2.  Primary:   Prostate Cancer Death Rates   [ Time Frame: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years. ]

3.  Secondary:   Deaths From All Causes   [ Time Frame: Events through 13 years of follow-up or through December 31, 2009. ]

4.  Secondary:   Death Rates From All Causes   [ Time Frame: Events through 13 years of follow-up or through December 31, 2009. ]

5.  Secondary:   Prostate Cancer Incidence   [ Time Frame: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years. ]

6.  Secondary:   Prostate Cancer Incidence Rates   [ Time Frame: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years. ]

7.  Secondary:   Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test   [ Time Frame: One year from screening examination ]

8.  Secondary:   T0 (Baseline) PSA Screening Results   [ Time Frame: T0 (at study entry) ]

9.  Secondary:   T0 (Baseline) DRE Screening Results   [ Time Frame: T0 (at study entry) ]

10.  Secondary:   T1 PSA Screening Results   [ Time Frame: T1 (one year after entry) ]

11.  Secondary:   T1 DRE Screening Results   [ Time Frame: T1 (one year after entry) ]

12.  Secondary:   T2 PSA Screening Results   [ Time Frame: T2 (two years after entry) ]

13.  Secondary:   T2 DRE Screening Results   [ Time Frame: T2 (two years after entry) ]

14.  Secondary:   T3 PSA Screening Results   [ Time Frame: T3 (three years after entry) ]

15.  Secondary:   T3 DRE Screening Results   [ Time Frame: T3 (three years after entry) ]

16.  Secondary:   T4 PSA Screening Result   [ Time Frame: T4 (four years after entry) ]

17.  Secondary:   T5 PSA Screening Results   [ Time Frame: T5 (five years after entry) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Paul F. Pinsky, Ph.D.
Organization: Early Detection Research Group, NCI, NIH
phone: 301-496-8544
e-mail: pinskyp@mail.nih.gov


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00002540     History of Changes
Other Study ID Numbers: NCI-2012-01755
NCI-2012-01755 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
PLCO-1
CDR0000078532
PLCO-Prostate ( Other Identifier: National Institutes of Health Clinical Center )
NCI-P93-0050 ( Other Identifier: DCP )
Study First Received: November 1, 1999
Results First Received: August 30, 2013
Last Updated: November 2, 2016
Health Authority: United States: Institutional Review Board